key: cord-0859629-8sjqntvn
authors: Sun, Yue; Yang, Angela Wei Hong; Hung, Andrew; Lenon, George Binh
title: Screening for a Potential Therapeutic Agent from the Herbal Formula in the 4(th) Edition of the Chinese National Guidelines for the Initial-Stage Management of COVID-19 via Molecular Docking
date: 2020-12-24
journal: Evid Based Complement Alternat Med
DOI: 10.1155/2020/3219840
sha: 37d8392d4afebe8ab816fd055562ffb0978cdb5e
doc_id: 859629
cord_uid: 8sjqntvn

BACKGROUND: COVID-19 caused by SARS-CoV-2 infection has been spreading through many countries since the end of 2019. The 4(th) edition of the national guidelines for the management of COVID-19 provides an herbal formula with 9 herbs for its management. Aim of Study. We aimed to predict the mechanism of binding of SARS-CoV-2 and SARS-CoV spike glycoproteins with angiotensin-converting enzyme 2 (ACE2) to provide a molecular-level explanation of the higher pathogenicity of SARS-CoV-2 and to identify protein sites which may be targeted by therapeutic agents to disrupt virus-host interactions. Subsequently, we aimed to investigate the formula for the initial-stage management to identify a therapeutic agent with the most likely potential to become pharmaceutical candidate for the management of this disease. MATERIALS AND METHODS: GenBank and SWISS-MODEL were applied for model creation. ClusPro was used for protein-protein docking. PDBePISA was applied for identification of possible binding sites. TCMSP was employed for identification of the chemical compounds. AutoDock Vina together with PyRx was used for the prediction and evaluation of binding pose and affinity to ACE2. SwissADME and PreADME were applied to screening and prediction of the pharmacokinetic properties of the identified chemical compounds. PyMOL was used to visualise the structural models of SARS-CoV-2 and SARS-CoV spike glycoproteins complexed to ACE2 and to examine their interactions. RESULTS: SARS-CoV-2 had two chains (labelled chains B and C) which were predicted to bind with ACE2. In comparison, the SARS-CoV had only one chain (labelled chain C) predicted to bind with ACE2. The spike glycoproteins of both viruses were predicted to bind with ACE2 via position 487. Molecular docking screening and pharmacokinetic property prediction of the herbal compounds indicated that atractylenolide III (−9.1 kcal/mol) from Atractylodes lancea (Thunb.) Dc. (Cangzhu) may be a candidate therapeutic agent for initial-stage management. CONCLUSIONS: Atractylenolide III is predicted to have a strong binding affinity with ACE2 and eligible pharmacokinetic properties, anti-inflammatory effects and antiviral effects in in vitro study, and high distribution on the lungs in in vivo study.

Coronavirus can cause multiple system infections including respiratory, digestive, and neurological systems in humans and other mammals [1] . e novel variant SARS-CoV-2 belongs to the subfamily of beta coronavirus. is makes the new virus the third zoonotic human coronavirus identified in this century. e last two zoonotic human coronaviruses which wreaked havoc in the global health system in the last CoV-2 Infection (Trial version 4), in most of the cases, the common symptoms are fever, drowsiness, and dry cough. In severe cases, serious symptoms may rapidly emerge, including acute respiratory distress syndrome, septic shock, metabolic acidosis, and coagulopathy. e susceptive groups are young children and elderly people [5] . Since the beginning of this epidemic, researchers have focused on new medications that could show potential to contain the transmission of the new virus and management of its collateral symptoms. e 4 th edition guidelines included the treatment including Chinese herbal medicine with 3 formulas to target 3 different stages of this disease. e symptoms in the initial stage of this disease are mild and relatively easy to manage compared to the severe stage. Herein, we aimed to investigate the modified herbal formula (Magnificent Atractylodes Rhizome powder; 神术散) designated for the management of the initial stage of this disease, namely, the stage of cold dampness stagnation in the lung, in Chinese medicine. It contains 9 herbs including e dosages of the ingredients are 15 grams for Atractylodes lancea ( unb.) Dc., 6 grams for both Amomum tsaoko Crevost et Lemarie and Ephedra sinica Stapf, and 10 grams for the rest of ingredients [5] . However, scientific evidence is presently lacking to justify the claim of its effectiveness for the management of this disease. e angiotensin-converting enzyme 2 (ACE2) receptor is viewed as the key protein in humans for the development of SARS-CoV-induced lung injury [6] . Since SARS-CoV-2 may target the same receptor to induce lung injury, it is proposed that computational molecular docking analysis is a feasible and rapid strategy to apply for the analysis of the interaction mechanism between the virus' spike glycoprotein and ACE2 receptor. However, there is presently no experimentally obtained structural model of the SARS-CoV-2 spike glycoprotein deposited yet in the Protein Databank (PDB) (http://www.rcsb. org). Despite several published and ongoing studies performed using docking analysis for the virus' proteins and ligands, the protein models applied in previous studies are based on the protein models from the SARS-CoV virus. However, the genetic data of the new viruses are available from GenBank (https://www.ncbi.nlm.nih.gov/genbank/). erefore, in this study, we have modelled the spike glycoprotein of SARS-CoV-2 to examine the difference between SARS-CoV-2 and SARS-CoV and, in particular, to provide a molecular-level understanding of the difference in transmissibility and pathogenicity of SARS-CoV-2 compared to SARS-CoV.

e binding sites of the binding complex of the spike glycoprotein of both viruses and ACE2 were identified. e chemical compounds from these 9 herbs were explored for their binding affinities with ACE2. Finally, the identified chemical compounds were screened for their pharmacokinetic properties including ADME and toxicity to find a therapeutic agent with good potential to be a pharmaceutical candidate.

Glycoprotein and Angiotensin-Converting Enzyme 2. e genetic information of SARS-CoV-2 spike glycoprotein in PubMed with accession number as YP 009724390.1.1 was extracted into a FASTA format file. is sequence was used as input data for homology modelling in SWISS-MODEL (https://swissmodel.expasy.org/). Among the results, Model 2 was selected because of the high values of Coverage, GMQE, and QMEAN. Further detailed information is presented in the Supplementary SWISS-MODEL building result file and structure assessment file. e ACE2 protein structure was extracted from the Protein Data Bank with the PDB ID 1R4L in the PDB format. e ClusPro online server (https://cluspro.bu.edu/queue.php) was applied to perform protein-protein docking for SARS-CoV-2 spike glycoprotein and ACE2. Model 0 was selected out of the top 10 models in the balanced order (Supplementary ClusPro protein-protein docking file). e complex structural model was created and visualised using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC., with various colours applied to label the different chains of these two proteins to facilitate visualization and interpretation.

e binding complex of these two proteins was extracted from Protein Data Bank with PDB ID 6ACG (https://www.rcsb. org/structure/6ACG) in PDB format. e structural model was created and visualised using PyMOL with various colours applied to label the different chains of these proteins to facilitate interpretation.

Angiotensin-Converting Enzyme 2. PDBePISA (https://www.ebi.ac. uk/pdbe/pisa/) was employed for the identification of binding chains and binding sites of the SARS-CoV-2/SARS-CoV spike glycoproteins and ACE2. e interface result and hydrogen bonds are summarized in Table 1 . e binding chains for the interactions of these two proteins were acquired from the interface result, while the binding sites were obtained from the results of the hydrogen bond analysis. Further detailed information is presented in the supplementary files with the file names as follows: SARS-CoV-2 and ACE2 interface results, SARS-CoV-2 chain B and ACE2 (chain D) binding sites result, SARS-CoV-2 chain C and ACE2 (chain D) binding sites result, SARS-CoV and ACE2 interface results, and SARS-CoV chain C and ACE2 (chain D) binding sites results. e above-identified binding chains and binding sites from these two viruses were compared to elucidate the similarity and difference. Evidence-Based Complementary and Alternative Medicine

Herbs. e TCMSP server (http://tcmspw.com/tcmsp.php) is an open online database with a large number of herbal entries with ADME properties, providing phytochemical information [7] .

e Chinese character names of the identified herbs were used as input data for the search (Table 2 ). e chemical compound results of each herb were screened by the designed selection criterion, namely, that the logP value is not more than 3. is is based on the theory that logP values of 2-3 had been recommended as the cutoff value for hydration, which has been established as a benchmark for the solubility of compounds [8] . e results were saved as PDB files via PubChem for further analysis. Chemical compounds without PubChem ID were extracted directly from the database. e chemical structures of the compounds with strong binding affinities (≥9 kcal/mol) are summarized in Table 3 in Results. e chemical structures for the compounds with binding scores in the range of −7 kcal/mol to −9 kcal/mol are presented in the supplementary table. Protonation states for titratable sidechains of the protein were based on those assigned using OpenBabel (OpenEye Scientific Software, Santa Fe, NM, USA) at pH 7. Gasteiger charges were applied to protein and ligands. Docking boxes were set using the "maximise" option in PyRx around the protein receptor in order to enable "blind" docking, in which the entire protein surface and accessible interior pockets were made available for potential binding of ligands. All dockings were performed with the default exhaustiveness value of 8. e dockings were semirigid, with full torsional flexibility allowed for the ligands, while the protein receptor structures were kept fixed. e cutoff value used to define strong binding affinity was set to be equal to or more than 7.0 kcal/mol. erefore, the compounds with binding affinity values higher than this value were excluded for further study.

e identified chemical compounds with binding affinity (≥7.0 kcal/mol) were searched in PubChem for antiviral activity evidence from bioassay results. e chemical compounds with active results from bioassay studies against respiratory infection virus that have similar symptoms with COVID-19 were summarized with the minimal concentrations, study types, and references provided in Table 4 .

e identified chemical compounds in PDB format were translated into MOL files using ChemDraw 3D version. SwissADME (http://www.swissadme.ch/) and PreADME (https://preadmet.bmdrc.kr/) were applied to predict pharmacokinetic properties including absorption, distribution, metabolism, and excretion (ADME) and toxicity. e results are summarized in a supplementary screening and prediction of ADME and toxicity table in terms of water solubility, Pharmacokinetic, Druglikeness, Medicinal Chemistry, Toxicity, and Eligibility. e screening criteria dictate that the chemical compound must be water-soluble, have high gastrointestinal absorption, satisfy Lipinski rule, Evidence-Based Complementary and Alternative Medicine 

Angiotensin-Converting Enzyme 2. e identified chemical compound and the ACE2 target were visualised in PyMOL to facilitate identification of specific residue interactions with active binding sites on the target. e PDBQT files of the binding ligand (chemical compound) and ACE2 obtained from AutoDock Vina were used as input files in PyMOL.

e binding sites were highlighted in different colours and labelled with residue names.

e predicted model of the SARS-CoV-2 spike glycoprotein and angiotensin-converting enzyme 2 illustrated the interactions of these two proteins. Figure 1 shows the SARS-CoV-2 spike glycoprotein coloured by its 3 different chains, with green for chain A, cyan for chain B, and red for chain C. ACE2 is coloured in magenta. Figure 1 indicates that the chain B and chain C of SARS-CoV-2 spike glycoprotein both contact ACE2.

For comparison, the predicted model of the SARS-CoV spike glycoprotein and angiotensin-converting enzyme 2 illustrating the interactions of these two proteins is shown in Figure 2 . e SARS-CoV spike glycoprotein is coloured by its 3 different chains, with green for chain A, cyan for chain B, and red for chain C. ACE2 is coloured in magenta. Inspection of the complex structural model shown in Figure 2 indicates that, in contrast to that of the SARS-CoV-2 spike glycoprotein, only chain C of the SARS-CoV spike glycoprotein is predicted to bind with ACE2.

e interface result of the PDBePISA analysis for the binding complex of SARS-CoV-2 Evidence-Based Complementary and Alternative Medicine spike glycoprotein and ACE2 confirmed that both the chain B and chain C of SARS-CoV-2 spike glycoprotein form binding contacts with ACE2 (chain D). Detail information regarding the interaction between each of the relevant protein chains, interface contact areas, and estimated free energies of interactions is listed in Table 1 . ese results suggest that chain B and chain C of the SARS-CoV-2 spike glycoprotein contribute to the interaction with ACE2, with an estimated binding ΔG of −11.2 kcal/mol and an estimated ΔG of −5.3 kcal/mol, respectively. e hydrogen bonds predicted to be formed between chain B of SARS-CoV-2 spike glycoprotein and ACE2 (chain D) showed that the main contributors to the interactions on chain B include THR333, ASN370, and ALA372. Likewise, the residues which make up binding sites on ACE2 included LYS600, SER254, and ALA614. e hydrogen bond-forming residues of chain C in SARS-CoV-2 spike glycoprotein include GLU484, GLN493, LYS417, ASN487, TYR489, GLN493, and TYR505. Likewise, the binding site residues on ACE2 which contribute to its interactions with SARS-CoV-2 chain C include ASP157, ASN159, ASP615, SER280, TYR252, and TYR613. Further detailed information regarding these key interactions is listed in Tables 5 and 6.

e interface result of the PDBePISA analysis for the binding complex of the SARS-CoV spike glycoprotein and ACE2 confirmed that the chain C of SARS-CoV spike glycoprotein is the only chain which forms close contact with ACE2 (chain D), in contrast to SARS-CoV-2 in which both chains B and C form close contact. Further detailed information is listed in Table 7 .

e hydrogen bond-forming residues of chain C in the SARS-CoV spike glycoprotein and ACE2 (chain D) complex showed that residues on chain C involved in binding ACE2 Table 8 .

Comparison of the predicted binding chains and binding sites of the complexes demonstrated that SARS-CoV-2 had two chains (chain B and chain C) binding with ACE2, while in contrast, the SARS-CoV only had one chain (chain C) binding with ACE2. Examination of the specific residues involved in binding indicates that there is one common residue, at position 487, which is used by both SARS-CoV-2 and SARS-CoV spike glycoproteins to bind with ACE2. Table 4 .

e chemical compound which satisfies the binding affinity and ADMET screening selection criteria is atractylenolide III from Atractylodes lancea ( unb.) Dc. (Cangzhu) with eligible water solubility, high GI absorption, eligible druglikeness and low hERG inhibition risk. All the other chemical compounds were excluded due to unsuitable water solubility, GI absorption, druglikeness, and toxicity. Specifically, oroxindin was excluded with the reason of low GI absorption. For Amomum tsaoko Crevost et Lemarie (Caoguo), quercetin 3-o-glucoside, hirsutrin, and hyperin were excluded due to low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. Quercetin 3o-rutinoside and quercetin 3-o-rhamnopyranosyl were excluded due to low GI absorption and violations of Lipinski's rules. For Citrus reticulata Blanco (Chenpi), hesperidin, hyperin, naringin, and orobanchoside were excluded due to low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. For Magnolia officinalis Rehd. et Wils. (Houpo) , neohesperidin was excluded for the reasons of low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. For Agastache rugosa (Huoxiang), acanthoside B, acteoside, and campneoside were excluded due to low GI absorption and violations of Lipinski's rules. For Notopterygium franchetii H. de Boiss (Qianghuo), chrysoeriol 7-rutinoside was excluded due to low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. Coumarin-glycoside was excluded due to low GI absorption and medium hERG inhibition risk. 6′-Feruloylnodakenin was ruled out due to low GI absorption, violations of Lipinski's rules, and medium hERG inhibition risk. For Ephedra sinica Stapf (Mahuang), cosmetin was excluded due to low GI absorption and high hERG inhibition risk. Hesperidin and luteolin 7-O-glucuronide were excluded due to low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. Rutin was excluded due to low GI absorption and violations of Lipinski's rules. Tilianine was excluded due to low GI absorption and medium hERG inhibition risk. Vitexin was excluded due to low GI absorption and high hERG inhibition risk. Further detailed information of each identified chemical compounds' pharmacokinetic property screening and prediction is summarized in Table 9 .

e molecular graphic of the docking residue is shown in Figure 3 , showing the predicted interaction between ACE2 and atractylenolide III, shown in ribbon form in magenta, and atractylenolide III, Evidence-Based Complementary and Alternative Medicine Evidence-Based Complementary and Alternative Medicine displayed as a "licorice" 3D structure. e key residues on ACE2 predicted to be involved in interaction with the ligand are also shown and involve a conventional hydrogen bond via ASN-149 (green) and pi-alkyl interaction via PHE 274 (yellow). As the binding results from hydrogen bond (H-bond) in chain B (Table 3) showed that SER254 can form a H-bond with SARS-CoV-2 spike glycoprotein. e binding results from hydrogen bond in chain C (Table 6) showed that ASP157, ASN159, TYR252 on ACE2 can form the H-bonds with SARS-CoV-2 spike glycoprotein. e ligand therefore binds in a region that shares a similar face as the ACE2 residues which are predicted to form contact with the SARS-CoV-2 spike glycoprotein. e ligand may therefore serve to disrupt, or weaken, ACE2-mediated virus-host cell interactions acting via this surface. A 2dimensional diagram showed that the ASN 149 binding site in ACE2 is connected with a hydroxyl group in the molecule.

e novel SARS-CoV-2 virus emerged to challenge the current medical system, exposing the shortfalls of existing pharmaceutical agents for its management.

e Chinese Health Commission included Chinese herbal medicine amongst its current recommendations for disease management and have prescribed herbal formulas from its 4 th edition of SARS-CoV-2 virus management guidelines.

In the initial stage, 9 herbs were prescribed for treating the symptoms, including chills, dry cough, dry throat, drowsiness, and chest tightness. Except Amomum tsaoko Crevost et Lemarie (Caoguo) and Areca catechu L. (Binglang), the other 7 herbs are among the highfrequency Chinese medicines for the management of pestilence throughout the history in China [19] . ACE2 receptors are viewed as the key protein in human for the development of SARS-CoV-induced lung injury [6] . Molecular docking was used to predict the binding mechanisms of both SARS-CoV-2 and SARS-CoV spike glycoproteins to ACE2, and it was identified that residue 487 for both viral proteins played a role in their binding to ACE2. e residue at position 487 for both SARS-CoV-2 and SARS-CoV spike glycoproteins has been proposed to be crucial for cross-species and human transmission for SARS-CoV [20] . Our results have echoed the findings from previous research that may strengthen the understanding of a similar role for the residue at this position of the new virus. Despite this similarity, there is still a large discrepancy between these two viruses in terms of binding chains and binding sites. ese differences may be contributed by their genomic sequence diversity [20] . e binding results showed that SARS-CoV-2 could have two chains binding with ACE2 receptor rather than SARS-CoV with one chain binding with ACE2. More chain bindings or interactions and more energy consumptions indicate much stronger binding affinity for this new virus [21, 22] . e simulation predicted that chain C for both viruses is critical for the binding activities with ACE2. For SARS-CoV-2, the residues in chain C are LYS 417, GLU 484, ASN 487, TYR 489, GLN 493, and TYR 505. From the findings in another in silico study with the same PDB ID (6ACG) protein for modelling, the residue in position 505 (−4.23 kcal/mol) plays an important role for spike glycoprotein of SARS-CoV-2 in terms of the binding energy contribution in comparison with the residues in position 487 (−1.5 kcal/mol) and 489 (−3.0 kcal/mol) [22] . From another in silico study, the amino acid residues ASN157, ASN159, and SER 280 have contributed to the solvent at the surface of the ACE2 molecule (PDB ID : 1RIX) in the binding with SARS-CoV spike glycoproteins [23] .

Molecular docking and pharmacokinetic screening were also used to identify atractylenolide III, from Atractylodes lancea ( unb.) Dc. (Cangzhu) as a therapeutic agent with strong binding affinity with ACE2, which also satisfy selection criteria based on pharmacokinetic properties. e key predicted binding site residues on ACE2 are ASN 149, which form a conventional hydrogen bond by one hydroxyl group in the molecule and ASN 149 in ACE2. e results from in vitro inhibition assay showed atractylenolide III with antiviral activity instead of the same analog testing compounds atractylenolide I and atractylenolide II. Since the hydroxyl group is the structural difference between atractylenolide III and the same analog compounds, it can be deduced that the hydroxyl group may play a key role in the inhibition effect against porcine reproductive and respiratory syndrome virus [10] . e existing evidence could support the therapeutic potential of atractylenolide III for its antiinflammatory activity, anti-porcine reproductive and respiratory syndrome virus activity, and heavy lung tissue distribution. Atractylenolide III (50 µM and 100 µM) possessed anti-inflammatory effects associated with the inhibition of nuclear factor-κB (NF-κB) and mitogenactivated protein kinases-(MAPK-) signaling pathways in lipopolysaccharide-(LPS-) induced RAW264.7 cells via suppression of the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumour necrosis factor-alpha (TNF-α), and interleukin 6 (IL-6) [24] . Intriguingly, atractylenolide III has been shown to possess inhibitory effects against porcine reproductive and respiratory syndrome virus, which is of importance in the swine industry. is virus can cause similar symptoms of SARS-CoV-2 respiratory infection including fever, cough, and dyspnea. e 50% inhibited concentration (IC 50 ) was 99.6 µmol/L for this compound [10] . Atractylenolide III had been found to have high concentration level in the lung tissues of rats in pharmacokinetics and tissue distribution experiments [25] . It may shed light on the therapeutic potential of this compound for new virusinduced respiratory infections and inflammations. Despite the fact that our findings suggested other compounds with antirespiratory viral activity, the pharmacokinetic properties of these compounds are not eligible to be used as drug candidates. erefore, atractylenolide III is the sole compound with antirespiratory activity and eligible pharmacokinetic properties to be considered as a drug candidate in our study. is finding is based on in silico study with limited evidence. It is noteworthy that there is no existing evidence from clinical studies to prove the efficacy of this formula. In order to acquire more solid evidential support, further in vitro and in vivo studies are required. e safety of Chinese herbal medicine is often a concern for its application and marketing. From the Chinese Pharmacopoeia 2015 edition, for the formula in the study, most of the herbs are safe to be applied but Citrus reticulata Blanco (dried tangerine peel; Chenpi), Ephedra sinica Stapf (ephedra; Mahuang), and Areca catechu L. (areca seed; Binglang) contain toxic substances. Aflatoxin can be found in both Citrus reticulata Blanco (dried tangerine peel; Chenpi) and Areca catechu L. (areca seed; Binglang). ere are strict restrictions for aflatoxin in these herbs. For both Citrus reticulata Blanco (dried tangerine peel; Chenpi) and Areca catechu L. (areca seed; Binglang), Aflatoxin B1 cannot exceed 5 µg per 1000 grams. Also, the total amount of aflatoxin G1, aflatoxin G2, aflatoxin B1, and aflatoxin B2 cannot be more than 10 µg. e toxic compound ephedrine in Ephedra sinica Stapf (ephedra; Mahuang) may raise the biggest concerns among all the herbs in the formula. A series of toxic events and adverse effects had been reported that included arrhythmia, hepatotoxicity, cardiovascular toxicity, and dilated pupils after application of ephedra. Despite such safety concerns, the safe application of ephedra can be safeguarded by different processing techniques [26] .

In conclusion, SARS-CoV-2 could bind with the ACE2 receptor at chain B and chain C to induce lung injuries in humans. e residue at position 487 may play a vital role as it did on SARS-CoV for the progression of lung injuries. Atractylenolide III is found to have a strong binding affinity with ACE2 by conventional hydrogen bond formation via ASN-149 and possess favourable pharmacokinetic properties, and it has been shown to exhibit anti-inflammatory effects and antiviral effects in a previous in vitro study and high distribution in the lungs in a previous in vivo study. All these findings support further research for the therapeutic effects of atractylenolide III for the management of this new virus.

Angiotensin-converting enzyme 2 ADME:

Absorption, distribution, metabolism, and excretion H-bond:

Hydrogen bond IL-6: Interleukin 6 LPS:

Lipopolysaccharide MAPK:

Mitogen-activated protein kinases MERS-CoV:

Middle East respiratory syndrome coronavirus NF-κB:

Nuclear factor-κB NO:

Nitric oxide PGE2:

Prostaglandin E2 SARS-Cov:

Severe acute respiratory syndrome coronavirus TNF-α:

Tumour necrosis factor-alpha WHO:

World Health Organization.

Data Availability e data are available upon request to the corresponding author.

e authors declare that they have no conflicts of interest.

Y. S. participated in information collection, computational analysis, and drafting. A. W. H. Y. and A. H. were responsible for writing, review, and editing. G. B. L. performed review and supervision. All authors read and approved the final manuscript.

Emerging coronaviruses: genome structure, replication, and pathogenesis

Return of the coronavirus: 2019-nCoV

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

COVID-19) Situation Report-180

Computational investigations of physicochemical, pharmacokinetic, toxicological properties and molecular docking of betulinic acid, a constituent of Corypha taliera (Roxb.) with Phospholipase A2 (PLA2)

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

TCMSP: a database of systems pharmacology for drug discovery from herbal medicines

Computational prediction of drug solubility in water-based systems: qualitative and quantitative approaches used in the current drug discovery and development setting

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Identification of porcine reproductive and respiratory syndrome virus inhibitors through an oriented screening on natural products

An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study

Discovery of potential multi-target-directed ligands by targeting hostspecific SARS-CoV-2 structurally conserved main protease

NTPase/helicase by dihydroxychromone derivatives

Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition

Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities

Synthesis and antiviral activity of substituted quercetins

Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses

Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

e binding mechanism of coronavirus disease 2019 with human angiotensin converting enzyme 2

Exploring the binding mechanism and accessible angle of SARS-CoV-2 spike and ACE2 by molecular dynamics simulation and free energy calculation

A model of the ACE2 structure and function as a SARS-CoV receptor

Anti-inflammatory activity of atractylenolide III through inhibition of nuclear factor-κB and mitogen-activated protein kinase pathways in mouse macrophages

Pharmacokinetics and tissue distribution of atractylenolide III in rats

Research on the toxicity of Ephedra